Clene Inc (CLNN)
NASDAQConsumer StaplesBiotechnologySnapshot 2026-11-04
$3.97-3.17%
Close 2026-11-05 · 1-day change
NASDAQConsumer StaplesBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · CLNN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
CLNN — debt issuance
Dated 2026-09-16
Entry into a Material Definitive Agreement. On September 15, 2026, Clene Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain existing stockholders, including certain of the Company’s directors and officers (the “Purchasers”), pursuant to which the Company agreed to issue and sell an aggregate of 1,219,513 shares of the Company’s common stock, par value $0.0001 per share (“common stock”), at an offering price of $3.28 per share.…
Why it matters: FDA acceptance would move the October application into review. A refusal or request for major changes would slow this path.
Supportive ifFDA accepts the NDA for review and sets a review timeline.
Worry ifFDA refuses to file the NDA or asks Clene to submit major new data before review.
Why it matters: The September offering was meant to fund operations through mid-first quarter 2027. A shorter runway could force another funding move.
Worry ifA later filing shows cash is too low to fund operations through mid-first quarter 2027. Or Clene raises new capital before then.
Less concerning ifClene says it has enough cash and low enough spending to fund operations through mid-first quarter 2027. It says this will not require new financing.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$251 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $656 loss on $10,000 · 6.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,149 loss on $10,000 · 51.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.